Tuberculosis and Respiratory Diseases

  • 제64권2호
  • /
  • Pages.95-101
  • /
  • 2008
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지

초치료 폐결핵 환자들에 있어서 초회 약제내성률

The Prevalence of Initial Drug Resistance among Pulmonary Tuberculosis Patients

  • 공재환 (단국대학교 의과대학 단국대학교병원 내과학교실) ;
  • 이상석 (단국대학교 의과대학 단국대학교병원 내과학교실) ;
  • 강하얀 (단국대학교 의과대학 단국대학교병원 내과학교실) ;
  • 박재석 (단국대학교 의과대학 단국대학교병원 내과학교실)
  • Kong, Jae Hwan (Department of Internal Medicine, Dankook University Hospital, College of Medicine, Dankook University) ;
  • Lee, Sang Seok (Department of Internal Medicine, Dankook University Hospital, College of Medicine, Dankook University) ;
  • Kang, Ha Yan (Department of Internal Medicine, Dankook University Hospital, College of Medicine, Dankook University) ;
  • Park, Jae Seuk (Department of Internal Medicine, Dankook University Hospital, College of Medicine, Dankook University)
  • 투고 : 2008.01.24
  • 심사 : 2008.02.01
  • 발행 : 2008.02.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

연구배경: 결핵의 치료력이 없는 결핵환자에서 발생하는 초회 약제내성은 결핵관리에 있어서 심각한 문제이다. 그러나 우리나라, 특히 민간의료기관에서 치료받는 폐결핵환자들의 초회 약제내성률에 대해서 잘 알려져 있지 않다. 본 연구에서는 천안지방의 한 3차병원에서 폐결핵환자들의 초회 약제내성률과 약제내성의 위험요소에 대해서 알아보았다. 방법: 2005년 9월부터 2007년 9월까지 단국대학교병원에서 객담 결핵균 배양검사 양성인 초치료 폐결핵환자 모두에 대해서 일차약과 이차약에 대한 약제감수성 검사를 시행하고 초회 약제내성의 양상과 함께 약제내성의 위험요소을 분석하였다. 또한 약제감수성 검사 결과가 치료 처방에 미치는 영향을 분석하였다. 결과: 총 156명의 초치료 폐결핵 환자에 대해서 약제 감수성 검사를 시행하였는데 한 가지 이상의 약제에 내성을 보인 환자는 21명(15.6%)이었으며 이소니아지드와 리팜핀에 동시 내성을 보이는 다제내성 환자는 1명(0.6%)이었다. 임상소견 중 초회 약제내성을 예측할 수 있는 독립적인 위험요소는 없었다. 약제감수성 검사 결과에 의해 15명(9.6%)의 환자에서 치료처방의 변경이 있었다. 결론: 폐결핵에서 초회 약제내성은 흔히 관찰되며 초 치료 폐결핵환자에서 약제감수성 검사는 환자치료에 도움이 된다.

Background: Drug resistant tuberculosis (TB) in patients who have not received previous TB treatment (initial drug resistance) is a serious problem for the control of TB. However, prevalence of initial drug resistance among pulmonary TB patients has not been well characterized in Korea, especially in the private sector. We assessed the prevalence of initial drug resistance and evaluated the risk factors for drug resistance in pulmonary TB patients, at a regional tertiary hospital in Cheonan. Methods: We performed a drug susceptibility test for both first and second line anti-TB drugs in all culture-confirmed pulmonary TB patients who had not received a previous TB treatment at Dankook University Hospital from September 2005 to September 2007. In addition, we evaluated the initial drug resistance pattern and clinical characteristics of patients to evaluate the risk factors for initial drug resistance. We also assessed the influence of the drug susceptibility test results on the treatment regimen. Results: Of the total 156 cases where the drug susceptibility test was performed, resistance to at least one anti-TB drug was found in 21 cases (15.6%) and multidrug resistance, where TB was resistant to at least isoniazid and rifampin, was found in one case (0.6%). Multivariate logistic regression showed no clinical characteristics were independently associated with initial drug resistance. Of the total 156 patients who underwent the drug susceptibility test, the treatment regimen was changed for 15 patients (9.6%) according to the results of the drug susceptibility test. Conclusion: Initial drug resistance is common and the drug susceptibility test is informative for pulmonary TB patients who have not received previous TB treatment.

키워드

참고문헌

  1. Hong Kong Tuberculosis Treatment Services/British Medical Research Council Investigation. A study in Hong Kong to evaluate the role of pretreatment susceptibility tests in the selection of regiments of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1972;106:1-22 https://doi.org/10.1164/arrd.1972.106.1.1
  2. Korean Academy of Tuberculosis and Respiratory Diseases. Guideline for the management of pulmonary tuberculosis, 1997. Tuberc Respir Dis 1997;44:1447-53
  3. American Thoracic Society/Center for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95 https://doi.org/10.1164/ajrccm.161.4.16141
  4. Korean Academy of Tuberculosis and Respiratory Diseases. Guideline for the management of pulmonary tuberculosis. Seoul: Korean Academy of Tuberculosis and Respiratory Diseases; 2005
  5. Bai GH. Anti-tuberculosis drug resistance in Korea. CDMR 2005;16:101-7
  6. Jung YJ, Park IN, Hong SB, Oh YM, Lim CM, Lee SD, et al. The clinical characteristics, diagnosis, treatment, and outcomes of patients with tuberculosis at a private university hospital in Korea. Tuberc Respir Dis 2006;60:194-204 https://doi.org/10.4046/trd.2006.60.2.194
  7. Son CH, Yang DK, Rho MS, Jeong JS, Lee H, Lee KN, et al. Prevalence of drug-resistances in patients with pulmonary tuberculosis and its association with clinical characteristics at one tertiary referral hospital in Pusan, Korea. Tuberc Respir Dis 2001;51:416-25 https://doi.org/10.4046/trd.2001.51.5.416
  8. Jeong SH, Lee DD, Choi JC, Kim SJ, Shin JH, Jeong JS, et al. Multi-center study on cost effectiveness of anti-tuberculosis drug susceptibility test. Infect Chemother 2005;37:16-21
  9. Choi JC, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Drug resistance rates of Mycobacterium tuberculosis at a private referral center in Korea. J Korean Med Sci 2007;22:677-81 https://doi.org/10.3346/jkms.2007.22.4.677
  10. National Tuberculosis Association of USA. Diagnostic standards and classification of tuberculosis. New York: National Tuberculosis Association; 1961
  11. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998;338:1641-9 https://doi.org/10.1056/NEJM199806043382301
  12. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002;185:1197-202 https://doi.org/10.1086/339818
  13. Koh HK, Kang YJ, Lim SY, Shin JW, Choi JS, Yoo JH, et al. Predictors of drug-resistance in patients with pulmonary tuberculosis. Tuberc Respir Dis 1999;46:311-6 https://doi.org/10.4046/trd.1999.46.3.311
  14. Min J, Park K, Whang S, Kim J. Risk factors for primary multidrug resistant tuberculosis. Tuber Respir Dis 2005;59:600-5 https://doi.org/10.4046/trd.2005.59.6.600
  15. Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. Infect Dis Clin North Am 1995;9:65-96
  16. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001;120:1514-9 https://doi.org/10.1378/chest.120.5.1514
  17. Kim DK, Kim MO, Kim TH, Sohn JW, Yoon HJ, Shin DH, et al. The prevalence and risk factors of drug resistant pulmonary tuberculosis investigated at one university hospital in Seoul. Tuberc Respir Dis 2005;58:243-7 https://doi.org/10.4046/trd.2005.58.3.243
  18. Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149:1359-74 https://doi.org/10.1164/ajrccm.149.5.8173779
  19. American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62 https://doi.org/10.1164/rccm.167.4.603
  20. Escalante P, Graviss EA, Griffith DE, Musser JM, Awe RJ. Treatment of isoniazid-resistant tuberculosis in southeastern Texas. Chest 2001;119:1730-6 https://doi.org/10.1378/chest.119.6.1730
  21. Koh WJ, Kwon OJ, Yu CM, Jeon K, Kim KC, Lee BH, et al. Treatment of isoniazid-resistant pulmonary tuberculosis. Tuberc Respir Dis 2004;56:248-60 https://doi.org/10.4046/trd.2004.56.3.248